OTCPK:ARLZQ - Post by User
Post by
dsilvermanon Nov 16, 2016 9:36am
154 Views
Post# 25467641
Adams shouldn't sell ARLZ for less than $25/Share.
Adams shouldn't sell ARLZ for less than $25/Share. We the shareholders, haven't suffered that far to just to get 20% return. Less than 2B market cap after yosprala approval with respect to toprol is a funny price. I've followed ARLZ sales managers in linkedin, they are the most honored pros in the u.s. With european approval for yosprala, potential sales can cross 500m and even more. So my call to every share holder here is to oppose selling the diamond for potato basket price.